TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02808689

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Factors
Description: Will look at nutrition and exercise that influence long-term health and chronic diseases.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Customized use of Dietary Supplements
Description: Reduce ongoing biologic imbalances from deficiencies in dietary oxidants/ antioxidants via vitamin supplementation. Approach is customized based on results for laboratory testing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Currently Accepted Asthma Care Guidelines
Description: Use of asthma care guidelines set forth by the National Institutes of Health/National Heart, Lung and Blood Institute (NIH/NHLBI) and Global Initiative for Asthma
Study: NCT02299024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional Opioid Information
Description: Patients receiving this intervention are given additional information about the opioid pain medication that they are receiving in the form of a one page handout. The hand out was written in a health-literacy appropriate manner. A research assistant read the handout to them out loud, and they were given a copy to take home with them.
Study: NCT03664492

Intervention type: OTHER
Group type: OTHER
Intervention: Educational whiteboard video
Description: Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
Study: NCT02551965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone nursing follow-up
Description: From the day of geriatric cancer patient's consultation, nurses will identify caregiver and will follow them by phone (caregiver) during 6 months
Study: NCT05871645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jakarta Surgical Uterine Conservation (JSICA) Technique
Description: a. Identifying the placenta accrete site; b. Meticulous dissection to create a bladder flap; c. Incision 1 cm above the placenta accrete; d. Fetal delivery; e. Bottom incision to resect the placenta; f. Placental delivery; g. Uterus without placenta; h. The resection area is approximated using interrupted horizontal mattress suture; i. The continuous suture used to close all incision areas; j. Evaluation of uterine contraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hysterectomy
Description: The main types of hysterectomy are abdominal, vaginal, and laparoscopic hysterectomy
Study: NCT03440268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetyl Cysteine
Description: Administrate NAC in the pre operatory and intra operatory moments and assess the influence in the outcomes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: These participants will receive a saline solution in pre operatory with the same volume as the experimental group, and this solution will be administrated in 2 hours. During the surgery they will receive a new solution with the same volume of the experimental group, and this solution will be administrated in 6 hours too. The solutions will be covered by an opaque bag, so the participant will not see what is being administrated
Study: NCT00662805

Intervention type: DRUG
Intervention: Salmeterol/Fluticasone propionate
Description: Open label, of Salmeterol/Fluticasone propionate (50/500 μg) twice daily via dry powder inhaler (DPI)
Study: NCT01084863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P6
Description: CT-P6: administered every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Herceptin: administered every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel: administered every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel: administered every 3 weeks
Study: NCT04061213

Intervention type: DIAGNOSTIC_TEST
Intervention: Tc-99m-DPD scintigraphy
Description: Myocardial scintigraphy
Study: NCT04433221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple sarcoma-specific CAR-T cells and sarcoma vaccines
Description: 1 infusion, CART 1x10\^6\~1x10\^7 cells/kg via IV and vaccines 1-5x10\^6 irradiated cells via subcutaneous injection
Study: NCT02154243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: 10 mg, p.o., once, on day of surgery after first physical therapy session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous fluid bolus
Description: 15 cc/kg, once, on day of surgery after first physical therapy session
Study: NCT03931538

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Guidance 4.0 PCR test
Description: All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Guidance 4.0 PCR test
Description: All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Guidance 4.0 PCR test
Description: All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine Culture
Description: All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine Culture
Description: All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine Culture
Description: All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
Study: NCT03726853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-497 200mg
Description: CKD-497 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-497 300mg
Description: CKD-497 300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-497 placebo
Description: Placebo of CKD-497

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CKD-497 placebo
Description: Placebo of CKD-497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Comparator
Study: NCT03080883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Given PO
Study: NCT00533299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine and magnesium valproate
Description: Hydralazine and valproate will start from seven days before day 1 of chemotherapy until the end of the sixth course. Hydralazine will be administered at 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebos will start from seven days before day 1 of chemotherapy until the end of the sixth course. Placebo tablets will be administered in an identical form that experimental drugs.
Study: NCT00713284

Intervention type: DRUG
Group type: OTHER
Intervention: sirolimus
Description: Oral tablet(s) taken daily for 6 months; dose will be based on serum trough levels.
Study: NCT00149890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight \<35 kg) or 20 mg (body weight ≥35 kg) strength.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight \<35 kg) or 20 mg (body weight ≥35 kg) strength.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine/cyclosporine microemulsion
Description: Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine/cyclosporine microemulsion
Description: Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid
Description: Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).
Study: NCT01431521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4074 200 mg
Description: 2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MK-4074
Description: 2 x 100-mg capsules, orally, BID for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride 30 mg
Description: 1 x 30-mg tablet, orally, once daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for pioglitazone hydrochloride
Description: 1 x 30-mg tablet, orally, once daily for 4 weeks
Study: NCT00952770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transradial coronary intervention
Description: percutaneous coronary intervention with transradial approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transradial coronary intervention
Description: percutaneous coronary intervention with transradial approach
Study: NCT04124224

Intervention type: OTHER
Intervention: Unidos
Description: The investigators will collaborate with our community partners to implement and evaluate a Community-Clinical Linkage (CCL) model in which Community Health Workers (CHWs) connect individuals to social determinant and community health services and build sociocultural resilience through CHW-facilitated individual and group support. As a public health practice-based study that incorporates evidence-based strategies, the investigators seek to establish Unidos effectiveness in Arizona counties with the highest percentage of Latinos of Mexican origin (Yuma, Pima, Santa Cruz, and Maricopa). Unidos CHWs, based in local health departments, will use evidence-based strategies to address three elements that are important in addressing chronic disease risk: 1) health promotion resources and programs; 2) individual and group-based social support; and 3) leveraging community resources to address social determinants of health.
Study: NCT01207869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ucMSCs
Description: the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: the same amount of ucMSCs suspension will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
Study: NCT02737293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet
Description: 4-week intake of Control Diet 5 day rotating menu

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Med Diet
Description: 4-week intake of Med Diet 5 day rotating menu

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Med Diet + Whole Egg
Description: 4-week intake of Med Diet plus Whole Egg 5 day rotating menu
Study: NCT00608244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP Tacro
Description: In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8.~LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses.~Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.
Study: NCT04332471

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial shockwave therapy
Description: Target intensity will be within a range of 3.5-5.0 bar at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Focused shockwave therapy
Description: Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave therapy device
Description: The shockwave therapy device will be used to administer either radial or focused shockwave therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave therapy device
Description: The shockwave therapy device will be used to administer either radial or focused shockwave therapy.
Study: NCT00269295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ty800
Description: Live attenuated Ty800 S typhi oral vaccine is co-administered with a sodium bicarbonate buffer solution. Dosages: 5 X 10\^7 cfu, 5 X 10\^8 cfu, and 5 X 10\^9 cfu.
Study: NCT04332471

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home therapy
Description: Stretching and ice massage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home therapy
Description: Stretching and ice massage
Study: NCT01270776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% aqueous chlorhexidine
Description: A single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Chlorhexidine 70% isopropyl alcohol
Description: single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
Study: NCT02535988

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of colorectal cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin
Description: Patients with metastatic lesions of colorectal cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
Study: NCT00753415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V935
Description: A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10\^9 vector genomes/mL) or a HD (1 x 10\^11 vector genomes/mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V935
Description: A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10\^9 vector genomes/mL) or a HD (1 x 10\^11 vector genomes/mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V935
Description: A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10\^9 vector genomes/mL) or a HD (1 x 10\^11 vector genomes/mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V935
Description: A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10\^9 vector genomes/mL) or a HD (1 x 10\^11 vector genomes/mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V935
Description: A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10\^9 vector genomes/mL) or a HD (1 x 10\^11 vector genomes/mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V934-EP
Description: A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V934-EP
Description: A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V934-EP
Description: A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V934-EP
Description: A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V934-EP
Description: A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V934-EP
Description: A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V934-EP
Description: A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).
Study: NCT00269295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ty800
Description: Live attenuated Ty800 S typhi oral vaccine is co-administered with a sodium bicarbonate buffer solution. Dosages: 5 X 10\^7 cfu, 5 X 10\^8 cfu, and 5 X 10\^9 cfu.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ty800
Description: Live attenuated Ty800 S typhi oral vaccine is co-administered with a sodium bicarbonate buffer solution. Dosages: 5 X 10\^7 cfu, 5 X 10\^8 cfu, and 5 X 10\^9 cfu.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.
Study: NCT01191424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF1535 NEXT DPI
Description: FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100µg PLUS FORMOTEROL FUMARATE 6 µg DRY POWDER INHALER

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP DPI and formoterol DPI
Description: FREE COMBINATION OF LICENSED BECLOMETHASONE DPI AND FORMOTEROL DPI
Study: NCT02451865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04233957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Sodium
Description: 10 days of 3900 mg of sodium/day in excess of normal dietary intake delivered via enteric capsules filled with table salt.
Study: NCT00753415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V934-EP
Description: A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).
Study: NCT02784808

Intervention type: DRUG
Intervention: Biological DMARDs
Description: Participants will receive biologic DMARDs as per standard of CARE. The choice of specific biologic DMARD will be at the descretion of treating physician.

Intervention type: DRUG
Intervention: Non-Biologic DMARDs
Description: Participants will receive non-biologic DMARDs as per standard of care. The choice of specific non-biologic DMARD will be at the descretion of treating physician.
Study: NCT02426437

Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary Rehabilitation (PR)
Description: Patients enrolled in PR will undergo a 6-8 week rehabilitation program.

Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary Rehabilitation (PR)
Description: Patients enrolled in PR will undergo a 6-8 week rehabilitation program.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients enrolled in usual care will be followed-up by their most responsible physician as determined by the admitting team.